What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?

Future Oncology

Volumn 11, Issue 1, 2015, Pages 153-167

  Pirker, Robert ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Advanced lung cancer; EGFR; monoclonal antibodies; targeted therapy; tyrosine kinase inhibitors

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; BMS 690514; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACOMITINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; NAVELBINE; NECITUMUMAB; NERATINIB; NIMOTUZUMAB; ONARTUZUMAB; PACLITAXEL; PANITUMUMAB; PELITINIB; PEMETREXED; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VANDETANIB; ANTIIDIOTYPIC ANTIBODY; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL MEDIATED CYTOTOXICITY; CHEMORADIOTHERAPY; DRUG MECHANISM; DRUG TARGETING; HUMAN; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT PLANNING; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; GENETICS; IMMUNOLOGY; PATHOLOGY;

ANTIBODIES, ANTI-IDIOTYPIC; CARCINOMA, NON-SMALL-CELL LUNG; ERBB RECEPTORS; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84921047049     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.178     Document Type: Review

References (104)

1. Azzoli CG, Temin S, Aliff T et al. 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 29(28), 3825-3831 (2011).
2. Azzoli CG, Baker S Jr, Temin S et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 27(36), 6251-6266 (2009).
3. Scagliotti GV, Parikh P, Von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 26(21), 3543-3551 (2008).
4. Fossella F, Pereira JR, Von Pawel J et al. Randomized, multinational, Phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J. Clin. Oncol. 21(16), 3016-3024 (2003).
5. Wang T, Nelson RA, Bogardus A, Grannis FW Jr. Five-year lung cancer survival: which advanced stage nonsmall cell lung cancer patients attain long-term survival? Cancer 116(6), 1518-1525 (2010).
6. Brabender J, Danenberg KD, Metzger R et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res. 7(7), 1850-1855 (2001).
7. Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol. 47(1), 9-19 (2008)
8. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J. Clin. Oncol. 20(18 Suppl.), S1-S13 (2002).
9. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl Acad. Sci. USA 101(36), 13306-13311 (2004).
10. Hirsch FR, Bunn PA Jr. EGFR testing in lung cancer is ready for prime time. Lancet Oncol. 10(5), 432-433 (2009).
11. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21), 2129-2139 (2004).
12. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676), 1497-1500 (2004).
13. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 64(24), 8919-8923 (2004).
14. Riely GJ, Politi KA, Miller VA, Pao W. Update on epidermal growth factor receptor mutations in non-small cell lung cancer. Clin. Cancer Res. 12(24), 7232-7241 (2006).
15. Choong NW, Salgia R, Vokes EE. Key signaling pathways and targets in lung cancer therapy. Clin. Lung Cancer 8(Suppl. 2), S52-S60 (2007).
16. Rosell R, Moran T, Queralt C et al. Screening for epidermal growth factor receptor mutations in lung cancer. N. Engl. J. Med. 361(10), 958-967 (2009).
17. Genentech. Full prescribing information erlotinib (TARCEVA®) (2012). www.gene.com
18. Roche Pharma AG. Summary of product characteristics erlotinib (TARCEVA®) (2010). www.europarl.europa.eu
19. Astra Zeneca AB. Summary of product characteristics gefitinib (IRESSA®) (2009). http://ec.europa.eu
20. Gao G, Ren S, Li A et al. Epidermal growth factor receptor tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six Phase III randomized controlled trials. Int. J. Cancer 131, E822-E829 (2012).
21. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012).
22. Zhou C, Wu YL, Chen G et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase 3 study. Lancet Oncol. 12(8), 735-742 (2011).
23. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
24. Douillard J-Y, Ostoros G, Cobo M et al. Efficacy, safety and tolerability results from a Phase IV, open-label, single arm study of 1st-line gefitinib in Caucasian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer. Presented at: European Multidisciplinary Conference in Thoracic Oncology (EMCTO). Lugano, Switzerland, 9-11 May 2013.
25. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J. Clin. Oncol. 25(12), 1545-1552 (2007).
26. Herbst RS, Prager D, Hermann R et al. TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol. 23(25), 5892-5899 (2005).
27. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 1. J. Clin. Oncol. 22(5), 777-784 (2004).
28. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a Phase III trial-INTACT 2. J. Clin. Oncol. 22(5), 785-794 (2004).
29. Janne PA, Wang X, Socinski MA et al. Randomized Phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J. Clin. Oncol. 30(17), 2063-2069 (2012).
30. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005).
31. Zhu CQ, Da Cunha Santos G, Ding K et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. J. Clin. Oncol. 26(26), 4268-4275 (2008).
32. Garassino MC, Martelli O, Broggini M et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 14(10), 981-988 (2013).
33. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366(9496), 1527-1537 (2005).
34. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised Phase III trial. Lancet 372(9652), 1809-1818 (2008).
35. Tan D, Deeb G, Wang J et al. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn. Mol. Pathol. 12(4), 201-211 (2003).
36. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin. Lung Cancer 10(4), 281-289 (2009).
37. Metro G, Crino L. The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Rev. Anticancer Ther. 11(5), 673-682 (2011).
38. Miller VA, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a Phase 2b/3 randomised trial. Lancet Oncol. 13(5), 528-538 (2012).
39. Yang JC, Shih JY, Su WC et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a Phase 2 trial. Lancet Oncol. 13(5), 539-548 (2012).
40. Sequist LV, Yang JC, Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31(27), 3327-3334 (2013).
41. Yang JC, Schuler MH, Yamamoto N et al. LUX-Lung 3: a randomized, open-label, Phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Presented at: 48th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 1-5 June 2012.
42. Katakami N, Atagi S, Goto K et al. LUX-Lung 4: a Phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol. 31(27), 3335-3341 (2013).
43. Wu YL, Zhou C, Hu CP et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised Phase 3 trial. Lancet Oncol. 15(2), 213-222 (2014).
44. Lee JS, Hirsh V, Park K et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind Phase III trial (ZEPHYR). J. Clin. Oncol. 30(10), 1114-1121 (2012).
45. Herbst RS, Sun Y, Eberhardt WE et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, Phase 3 trial. Lancet Oncol. 11(7), 619-626 (2010).
46. Natale RB, Thongprasert S, Greco FA et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J. Clin. Oncol. 29(8), 1059-1066 (2011).
47. De Boer RH, Arrieta O, Yang CH et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind Phase III trial. J. Clin. Oncol. 29(8), 1067-1074 (2011).
48. Ross HJ, Blumenschein GR Jr, Aisner J et al. Randomized Phase II multicenter trial of two schedules of lapatinib as first-or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin. Cancer Res. 16(6), 1938-1949 (2010).
49. Sequist LV, Besse B, Lynch TJ et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a Phase II trial in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 28(18), 3076-3083 (2010).
50. Ramalingam SS, Blackhall F, Krzakowski M et al. Randomized Phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 30(27), 3337-3344 (2012).
51. Mok T, Kris M, Ou S et al. Efficacy, safety, and patient-reported outcomes of first-line dacomitinib (PF-00299804), an irreversible pan-her tyrosine kinase inhibitor, in patients with lung cancers harboring EGFR exon 21 mutation or EGFR exon 19 deletion. Presented at: 5th Asia Pacific Lung Cancer Conference. Fukuoka, Japan, 25-28 November 2012.
52. Mok T, Nakagawa K, Rosell R et al. Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s). Presented at: 49th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 31 May-4 June 2013.
53. Boehringer Ingelheim. A randomised, open-label Phase IIb trial of afatinib versus gefitinib as first-line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung (2014). http://clinicaltrials.gov/show/NCT01466660
54. Bristol-Myers Squibb. A double-blind, randomized, parallel two-arm Phase II trial of BMS-690514 versus erlotinib in previously treated NSCLC patients (2013). http://clinicaltrials.gov
55. Wyeth. A Phase 2 study of EKB-569 in subjects with advanced non-small cell lung cancer (2009). http://clinicaltrials.gov
56. Schuler MH, Yang C-H, Park K et al. Continuation of afatinib beyond progression: results of a randomized, open-label, Phase III trial of afatanib plus paclitaxel versus investigator's choice chemotherapy in patients with metastatic non-small cell lung cancer progressed on erlotinib/gefitinib and afatanib-LUX-Lung 5. Presented at: 50th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2014.
57. Boehringer Ingelheim. LUX-Lung 8: A randomized, open-label Phase III trial of afatinib versus erlotinib in patients with advanced squamous cell carcinoma of the lung as second-line therapy following first-line platinum-based chemotherapy (2014). http://clinicaltrials.gov/show/NCT01523587
58. Ramalingam SS, Janne PA, Mok T et al. Randomized, double-blinded study of dacomitinib, an irreversible panhuman epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009). Presented at: 50th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2014.
59. Ellis PM, Liu G, Millward M et al. NCIC CTG BR.26: a Phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. Presented at: 50th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2014.
60. Boehringer Ingelheim Pharmaceuticals. Full prescribing information afatinib (GILOTRIF™) (2013). www.accessdata.fda.gov
61. Janjigian YY, Groen HJ, Horn L et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. Presented at: 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 3-6 June 2011.
62. Janjigian YY, Smit EF, Horn L et al. Activity of afatinib/cetuximab in patients with EGFR mutant non-small cell lung cancer and acquired resistance to EGFR inhibitors. Presented at: 37th European Society of Medical Oncology Congress. Vienna, Austria, 28 September-2 October 2012.
63. Keedy VL, Temin S, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 29(15), 2121-2127 (2011).
64. Pirker R, Herth FJ, Kerr KM et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J. Thorac. Oncol. 5(10), 1706-1713 (2010).
65. D'addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v116-v119 (2010).
66. Felip E, Garrido P, Trigo JM et al. SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clin. Transl. Oncol. 11(5), 284-289 (2009).
67. Lazzari C, Novello S, Barni S et al. Randomized proteomic stratified Phase III study of second-line erlotinib versus chemotherapy in patients with inoperable non-small cell lung cancer (PROSE). Presented at: 49th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 31 May-4 June 2013.
68. ImClone LLC. Full prescribing information ERBITUX® (cetuximab) (2013). http://packageinserts.bms.com/pi/pi-erbitux.pdf
69. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised Phase III trial. Lancet 373(9674), 1525-1531 (2009).
70. Pirker R, Pereira JR, Von Pawel J et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the Phase 3 FLEX study. Lancet Oncol. 13(1), 33-42 (2012).
71. Lynch TJ, Patel T, Dreisbach L et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter Phase III trial BMS099. J. Clin. Oncol. 28(6), 911-917 (2010).
72. Crawford J, Sandler AB, Hammond LA et al. ABX-EGF in combination with paclitaxel and carboplatin for advanced non-small cell lung cancer (NSCLC). Presented at: 40th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 5-8 June 2004.
73. Mekhail T, Waterhouse DM, Hadley TJ et al. First-line carboplatin, pemetrexed, and panitumumab in patients with advanced nonsquamous KRAS wild type non-small cell lung cancer. Presented at: 49th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 31 May-4 June 2013.
74. Prabhash K, Babu KG, Vaid AK et al. Nimotuzumab plus chemotherapy versus chemotherapy alone in advanced non-small cell lung cancer: a Phase II, open-label, multicenter, randomized study. Presented at: 49th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 31 May-4 June 2013.
75. Paz-Ares L, Miziara JE, Losonczy G et al. Randomized Phase-3 trial (INSPIRE) of necitumumab plus cisplatin-pemetrexed versus cisplatin-pemetrexed alone as first-line therapy in stage IV non-squamous NSCLC. Presented at: 15th World Congress on Lung Cancer. Sydney, Australia, 27-30 October 2013.
76. Daiichi Sankyo Company, Ltd. Daiichi Sankyo enrolls first patient in nimotuzumab Phase 3 clinical trials (2013). www.daiichisankyo.com
77. Thatcher N, Hirsch FR, Szczesna A et al. A randomized, multicenter, open-label, Phase III study of gemcitabine-cisplatin chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. Presented at: 50th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2014.
78. Kurai J, Chikumi H, Hashimoto K et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin. Cancer Res. 13(5), 1552-1561 (2007).
79. Rosell R, Robinet G, Szczesna A et al. Randomized Phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol. 19(2), 362-369 (2008).
80. Butts CA, Bodkin D, Middleman EL et al. Randomized Phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J. Clin. Oncol. 25(36), 5777-5784 (2007).
81. Lynch T, Bhagavatheeswaran P, Mukhopadhyay P, Khambata-Ford S, Harbison CT. A retrospective subgroup analysis of EGFR immunohistochemistry (IHC) expression by histo-score correlated to outcomes from the BMS099 1st line Phase III NSCLC trial of cetuximab (Cet) plus carboplatin/taxane. Eur. J. Cancer 47(Suppl. 1), 591-592 (2011).
82. O'Byrne KJ, Gatzemeier U, Bondarenko I et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the Phase 3 FLEX study. Lancet Oncol. 12(8), 795-805 (2011).
83. Khambata-Ford S, Harbison CT, Hart LL et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a Phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 28(6), 918-927 (2010).
84. Gatzemeier U, Von Pawel J, Vynnychenko I et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX Phase 3 study. Lancet Oncol. 12(1), 30-37 (2011).
85. Foon KA, Yang XD, Weiner LM et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int. J. Radiat. Oncol. Biol. Phys. 58(3), 984-990 (2004).
86. Freeman DJ, Bush T, Ogbagabriel S et al. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol. Cancer Ther. 8(6), 1536-1546 (2009).
87. Amgen, Inc. Full prescribing information panitumumab (VECTIBIX®) (2009). www.accessdata.fda.gov
88. Socinski MA. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab. Clin. Cancer Res. 13(15 Pt 2), s4597-s4601 (2007).
89. Topper MB, Tonra JR, Pytowski B, Eastman SW. Differentiation between the EGFR antibodies necitumumab, cetuximab, and panitumumab: antibody internalization and EGFR degradation. Presented at: 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 3-6 June 2011.
90. Patel D, Saxena B, Zhou Q et al. Differential induction of antibody-dependent cellular cytotoxicity (ADCC) against human EGFR-expressing NSCLC cell lines by necitumumab, cetuximab, and panitumumab. 47th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 3-6 June 2011.
91. Samakoglu S, Deevi DS, Li H et al. Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC. Cancer Genomics Proteomics 9(2), 77-92 (2012).
92. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7(3), 169-181 (2007).
93. Bahleda R, Soria J, Harbison C et al. Tumor regression and pharmacodynamic (PD) biomarker validation in non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor BMS-690514. Presented at: 45th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 29 May-2 June 2009.
94. Yoshimura N, Kudoh S, Kimura T et al. EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib. Lung Cancer 51(3), 363-368 (2006).
95. Janne PA, Ramalingam SS, Yang JC-H et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer. Presented at: 50th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2014.
96. Sequist L, Soria J-C, Gadgeel S et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). Presented at: 50th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2014.
97. Cappuzzo F, Janne PA, Skokan M et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol. 20(2), 298-304 (2009).
98. Cappuzzo F, Marchetti A, Skokan M et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J. Clin. Oncol. 27(10), 1667-1674 (2009).
99. Spigel D, Ervin T, Ramlau R et al. Randomized multicenter double-blind placebo-controlled Phase II study evaluating MetMAb, an antibody to Met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer. Presented at: 35th European Society for Medical Oncology Congress. Milan, Italy, 8-12 October 2010.
100. Sequist LV, Von Pawel J, Garmey EG et al. Randomized Phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J. Clin. Oncol. 29(24), 3307-3315 (2011).
101. Spigel DR, Edelman MJ, O'Byrne K et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: results from the pivotal Phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. Presented at: 50th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2014.
102. Scagliotti G, Novello S, Ramlau R et al. MARQUEE. A randomized, double-blind, placebo-controlled, Phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small-cell lung cancer. Presented at: European Cancer Congress 2013 (ECCO-ESMO-ESTRO). Amsterdam, The Netherlands, 27 September-1 October 2013.
103. Novello S, Scagliotti G, Ramlau R et al. Efficacy analysis for molecular subgroups in MARQUEE: a randomized, double-blind, placebo-controlled, Phase 3 trial of tivantinib (ARQ 197) plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer. Presented at: 15th World Conference on Lung Cancer. Sydney, Australia, 27-31 October 2013.
104. Azuma K, Yoshioka H, Yamamoto N et al. Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: first report of a Phase III ATTENTION trial. Presented at: 50th Annual Meeting of the American Society of Clinical Oncology. Chicago, IL, USA, 30 May-3 June 2014.